Skip to main content

Published locations for Commentary: New Horizons in NSCLC Treatment: Adagrasib, Aumolertinib, and Lorlatinib, July 2022

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Commentary: New Horizons in NSCLC Treatment: Adagrasib, Aumolertinib, and Lorlatinib, July 2022

User login

  • Reset your password
  • /content/commentary-new-horizons-nsclc-treatment-adagrasib-aumolertinib-and-lorlatinib-july-2022
  • /hematology-oncology/article/256001/lung-cancer/commentary-new-horizons-nsclc-treatment-adagrasib